Efficacy and tolerability of indacaterol 75 μg once daily in patients aged≥ 40 years with chronic obstructive pulmonary disease: results from 2 double-blind, placebo …
EM Kerwin, MH Gotfried, D Lawrence, C Lassen… - Clinical …, 2011 - Elsevier
BACKGROUND: Indacaterol is the first once-daily, long-acting, inhaled β2-agonist
bronchodilator for maintenance treatment of chronic obstructive pulmonary disease (COPD).
Two studies (previously reported in a Congress abstract) were performed in 2010 to provide
efficacy and tolerability data to support the application for approval in the United States of
indacaterol 75 μg once daily, a dose lower than that previously investigated in most studies.
OBJECTIVE: The primary objective was to evaluate the efficacy of indacaterol 75 μg once …
bronchodilator for maintenance treatment of chronic obstructive pulmonary disease (COPD).
Two studies (previously reported in a Congress abstract) were performed in 2010 to provide
efficacy and tolerability data to support the application for approval in the United States of
indacaterol 75 μg once daily, a dose lower than that previously investigated in most studies.
OBJECTIVE: The primary objective was to evaluate the efficacy of indacaterol 75 μg once …
以上显示的是最相近的搜索结果。 查看全部搜索结果